FAQ's: Drug Repurposing for Sarcoma Patients

Q: How do I take part in this study?

A: Simply go to https://xcures.com/details/cdrc/ and follow the instructions.

Q: What are the goals of this study? Why is this study being done?

A: This study is being done for several reasons:

- to better understand the current treatments being used for rare and ultra-rare sarcomas.
- to capture de-identified real-world patient data that can be shared with clinicians, researchers, patients and all stakeholders in a public open platform.
- to identify potential FDA approved drugs or supplements that improve outcomes (or cause harm) but have not been labeled for the indication.
- to develop hypotheses for clinical trials and better design future clinical trials
- to share real-time information to help identify treatments and to make better treatment decisions.
- to identify safe and effective drugs that are already available but lack sufficient clinical evidence to support their use in a new way.

Q: Why should I participate in this study?

A: Our aim is to better understand the current treatments being used for rare and ultra-rare sarcomas. Your medical records and patient information are the best sources to find out the drugs you have taken and the treatments you have tried. By gathering and sharing this information, we hope it can help families choose better treatments in the future.

The drug repurposing data that xCures collects will be not include any personal information and made HIPAA Safe Harbor Law compliant (HR7898) to protect patients' identities. In doing so, CURE ID will be able to publicly release each de-identified data set and collectively analyze these data to generate hypotheses that a repurposed drug is either effective, does not alter outcomes, or is harmful. Having this information made publicly available can generate interest in testing these hypotheses in clinical trials.

Q: Who is xCures?

A: xCures Inc. is a well-known US-based organization that operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated

and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time. The platform's portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions. The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials.

For more information, visit the xCures website at www.xCures.com

Q: What does xCures do?
A: The xCures technology platform automatically creates a comprehensive outline of a cancer patient's medical history generated from the hospitals and clinics visited. Patients get immediate access to the care summary and all of their medical data in one easy-to-access place. For more information, visit the xCures website at www.xCures.com

Q: What is CURE Drug Repurposing Collaboratory (CDRC)?
A: CDRC is a public-private partnership led by the Critical Path Institute (C-Path), a non-profit 501(c)3 organization dedicated to catalyzing the development of new approaches to advance medical innovation and regulatory science. Initiated in June 2020 by C-Path and the U.S. Food and Drug Administration (FDA) in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), CDRC is designed to capture real-world clinical outcome data to advance drug repurposing and inform future clinical trials for diseases of high unmet medical need.

Q: What is CURE ID?
A: CURE ID is an internet-based repository that lets the clinical and patient communities report use of drugs for difficult-to-treat diseases through a website, a smartphone or other mobile device. The platform enables the crowdsourcing of medical information from health care providers, patients, and care partners to identify existing drugs that may be effective treatments for diseases that lack incentives for the development of new therapies. URE ID was developed through the collaboration of the FDA and the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). FDA and NIH are also collaborating with the World Health Organization and the Infectious Diseases Society of America to assess the global utility of the CURE ID. With support from FDA's Oncology Center of Excellence (OCE), CURE ID is expanding beyond infectious diseases, to capture cases of drug repurposing for rare cancers, and other rare diseases

Q: What is Drug Repurposing (also known as off-label use)?

A: Drug repurposing involves identifying FDA-approved drugs that may be effective for diseases they're not currently approved for. Drug repurposing includes drugs that are being used in a new way, such as to treat a different disease from the one it was originally studied and approved to treat; in a new dose, route, or duration; in a new combination with other drugs or non-pharmacologic treatments, or in a new population (e.g., pregnant patients, pediatrics, neonates, etc.).

Q: How do I know if the drug I am taking is repurposed?

A: You can find out if a drug you take is repurposed by looking at the drug label at this website: https://dailymed.nlm.nih.gov/dailymed/index.cfm . Enter the name of the drug you take in the search box. Look at the section called "Indications and Usage." If the reason you take the drug is listed in this section, then it is not repurposed. If the reason you are taking the drug is not listed in this section, then it means the drug is being used "off-label" and is an example of a repurposed drug. Repurposed drugs may also describe drugs that are being used for the same disease, but in a very different way such as a larger or smaller dose, or longer or shorter period of time than usual.

Q: What is an example of a repurposed drug?

A: Two examples for angiosarcoma are:

1. Beta-blockers, like a medicine called propranolol, are used by doctors to help with heart problems. They're approved by the FDA to manage heart issues. However, some patients take them for angiosarcoma.
2. mTOR inhibitors (e.g sirolimus, also known as rapamycin) is an FDA approved immunosuppressant used to coat coronary stents, prevent organ transplant rejection, and treat a rare lung disease called lymphangioleiomyomatosis. It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. However, some EHE & PEComa patients use this drug.

Q: Who is responsible for this study?

A: xCures Inc. is responsible for the study and for giving you written notices, forms, and other information about your participation in the study. xCures Inc. is a US-based organization made up of leading physicians, biomedical scientists, patient advocates and computer scientists.
See data flow chart for more information.

Q: Who can join this study?

A: Anyone with a sarcoma subtype who lives in, receives treatment in, or will be traveling for treatment to the United States or U.S. territories can join the study. If you are the parent of a minor child with sarcoma or are the legally authorized representative of someone with sarcoma, you can sign up and they can participate.

Q: What partners will be engaged?

A: FDA and NCATS/NIH host the CURE ID platform which will be used to gather cases of sarcoma treatment with repurposed drugs.

Partners and Collaborators:

- xCures
- The EHE Foundation

- Sarcoma Foundation of America
- Clear Cell Sarcoma Foundation
- EveryCure
- Colorado University Anschutz Medical Campus
- University of Michigan Rogel Cancer Center
- AntiCancer Fund
- MIB Agents
- Memorial Sloan Kettering Cancer Center
- National Leiomyosarcoma Foundation
- CDRC
- NCATS/NIH
- U.S. FDA

Q: Where will my data be stored?

A: All of your data will be stored on xCures in a secure and encrypted database that is compliant with 21 CFR Part 11. Electronic Data Capture (EDC) systems, that are Part 11 compliant, meet the FDA's criteria for security and accuracy. This data will not be publicly available.

Q: Who will have access to my data?

A: xCures = not publicly available.

Only authorized persons on the study team have access to your identifiable information. Information and data about you may be shared with other researchers in the future, but your identifying information will not be shared or disclosed outside of the study team without your permission.

xCures may use privacy preserving technology to help find and link your data collected for research with data from other researchers. This technology is called tokenization and allows researchers, including the study team, to confirm your data without sharing any identifying information about you.

CURE ID= publicly available.

xCures will share a small portion of the data with CURE ID after any information that could identify you is removed. This information will be published on CURE ID as a publicly available case report. The case report will not include information that identifies you.

Q: Who owns my study data?
A: Patients remain the data owners. At any point you can choose to withdraw your data; however, please note that upon withdrawing from the study, xCures may use the de-identified data that has already been collected for research purposes. If you have any questions about this process or would like to withdraw your data, please send a message to help@xcures.com.

Q: Can I see the information you collect about me?
A: Access the xCures Patient Portal to review your data. Upon registration completion, your medical records will be aggregated and available for you to review in the patient portal. Once your medical records are received, the xCures team uses AI assisted technology to create your Cancer Care Summary, which includes information about your diagnosis and tumor genomic features, previous treatments and procedures, and tracking of your overall well-being. This report, and all of your collected medical documents, will be available for you to download directly from the patient portal.

Q: How will my private information be protected?
A: The security of your data is very important to xCures. They meet or exceed the physical, technical, and administrative security requirements of HIPAA and continue to improve their ability to safeguard data and measure their state of compliance. For details, please read their Privacy Policy: https://xcures.com/privacy-policy/.

Q: Will it cost me anything to take part?
A: There is no cost to participate in the study. You will not be charged for any of xCures' services.

Q: Will I be paid for taking part in the study?
A: You will not be paid for taking part in the study.

Q: How long will this study last?
A: This is an ongoing research initiative funded by FDA. Based on the availability of funding every subject will be followed indefinitely until they are deceased. The study will continue for up to two years after all study subjects are deceased for additional data analysis and publication.

Q: What if I change my mind about taking part in this study?
A: At any point you can choose to withdraw your data, please send a message to help@xcures.com to do so.

If you change your mind about being in the study, you can stop participating at any time by notifying the study team in writing by emailing help@xcures.com. If you no longer want us to contact you, you or a caregiver can notify us at the email listed. If you stop participating in the study, we will no longer contact you about the study, but we will keep the information that has been collected about you for research purposes. If you leave the study, the data that were already collected may still be used for this study. No new data will be collected or used. Please feel free to reach out to help@xcures.com with any questions about this process.

Q: Will my doctor(s) be contacted?
A: If you identify your doctor's or care team's contact information during registration, we will reach out once you have completed registration in order to let them know that you are participating in our research protocol and have requested treatment insights from us. We may also contact your

physician or treating institution when needed to obtain medical records to provide our services to you and/or when we have done so and are prepared to share a Care Summary or Treatment Options Report for you each to review. To note, in order for you to receive a Treatment Options Report, xCures must have documented approval from your physician. That being said, your doctor or care team's contact information is not required to complete our registration and participate. Additionally, if you'd prefer, we not reach out to your doctor or care team, we will not do so.

Q: Does this study change my care?
A: No. This study is non-interventional. Non-interventional means your regular healthcare provider makes all the decisions about your treatment. You should still be in contact your healthcare provider.

Q: Can I join another study if I join this study?
A: Yes! There are no restrictions on joining other studies. Please let us know if you enroll in other studies by emailing help@xcures.com.

Q: Where can I learn more?
A: To learn more please visit:

- visit xCures at https://xcures.com/details/cdrc/
- contact your sarcoma foundation representative
- email CDRC at cdrc@c-path.com
- visit https://clinicaltrials.gov/ct2/show/NCT03793088

Patient Data Flow



CURE ID Disclaimer

CURE ID is an independently populated database for use by healthcare providers and public health officials to report information on disease case studies. Patients and care partners may

now also share case reports describing their treatment experiences on the platform. However, case study submissions are expected to meet certain criteria and FDA and NIH maintain the right to remove submissions that do not meet the inclusion criteria listed below. FDA and NIH also reserve the right to remove cases which are flagged as highly suspect by users (e.g., such treatment was not used, case was made up, dangerous suggestion, etc.) or otherwise inappropriate or offensive.